Advantages of switching to elvitegravir/cobicistat/emtricitabine/tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome.

ABSTRACT:

SUBMITTER: Fan L 

PROVIDER: S-EPMC9945251 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature